ArticleBMC neurology2026
Posterior reversible encephalopathy syndrome in the setting of severe systemic lupus erythematosus activity with a rapidly fatal outcome: a case report.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPosterior reversible encephalopathy syndrome (PRES) is typically considered a self-limiting neurological disorder with a favorable prognosis when promptly diagnosed and treated. However, we report a rare fulminant case of PRES in a patient with systemic lupus erythematosus (SLE), challenging the notion of its uniformly benign course. CASE PRESENTATION: A 50-year-old Asian woman with a recent diagnosis of active SLE and dialysis-dependent renal failure presented with an 8-hour history of headache, dizziness, visual impairment, and seizures. Brain MRI revealed bilateral parieto-occipital lesions consistent with PRES. Diffusion-weighted imaging (DWI) showed mixed hyperintensity corresponding to low signal on the apparent diffusion coefficient (ADC) map, confirming true diffusion restriction and indicating cytotoxic edema. Despite immediate admission to the neurological intensive care unit and administration of corticosteroids, antihypertensives, and antiepileptics, the patient experienced rapid neurological deterioration. Within 70 min, she developed massive oral and nasal bleeding, followed by cardiac arrest and death. Laboratory tests showed moderate thrombocytopenia, but no platelet transfusion was administered per current guidelines due to the absence of active bleeding at the time of admission.
conclusionsThis case highlights a fulminant and multifactorial clinical course of severe systemic lupus erythematosus, in which PRES represented a secondary neurological manifestation rather than the primary cause of death. It underscores the importance of recognizing PRES in patients with active SLE as a marker of severe systemic disease activity and emphasizes the need for prompt multidisciplinary evaluation and comprehensive management of underlying systemic involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.